By Mill Chart
Last update: May 15, 2024
Discover UNITED THERAPEUTICS CORP (NASDAQ:UTHR)—an undervalued stock our stock screener has picked out. NASDAQ:UTHR demonstrates solid fundamentals, including health and profitability, all while staying attractively priced. Let's explore the details.
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:UTHR has received a 8 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:UTHR scores a 8 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:UTHR has earned a 7 out of 10:
Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:UTHR boasts a 6 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
For an up to date full fundamental analysis you can check the fundamental report of UTHR
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
UNITED THERAPEUTICS CORP
NASDAQ:UTHR (5/24/2024, 7:02:18 PM)
After market: 272.88 0 (0%)272.88
-3.62 (-1.31%)
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals.
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.